Search

Author/Creator Marabelle, A

1. T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. (29th March 2019)

Authors:
Messaoudene, M; Mourikis, T P; Michels, J; Fu, Y; Bonvalet, M; Lacroix-Trikki, M; Routy, B; Fluckiger, A; Rusakiewicz, S; Roberti, M P; Cotteret, S; Flament, C; Poirier-Colame, V; Jacquelot, N; Ghiringhelli, F; Caignard, A; Eggermont, A M M; Kroemer, G; Marabelle, A; Arnedos, M
Journal:
Annals of oncology
Issue:
Volume 30:Number 6(2019)
Page Start:
934
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 3OApplicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. (27th February 2019)

Authors:
Varga, A; Bernard-Tessier, A; Auclin, E; Mezquita Pérez, L; Baldini, C; Planchard, D; Marabelle, A; Hollebecque, A; Besse, B; Massard, C
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. (10th September 2018)

Authors:
Smoragiewicz, M; Bogaerts, J; Calvo, E; Marabelle, A; Perrone, A; Seymour, L; Shalabi, A; Siu, L L; Tabernero, J; Giaccone, G
Journal:
Annals of oncology
Issue:
Volume 29:Number 11(2018)
Page Start:
2175
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). (8th October 2018)

Authors:
Marabelle, A; Andtbacka, R; Harrington, K; Melero, I; Leidner, R; de Baere, T; Robert, C; Ascierto, P A; Baurain, J -F; Imperiale, M; Rahimian, S; Tersago, D; Klumper, E; Hendriks, M; Kumar, R; Stern, M; Öhrling, K; Massacesi, C; Tchakov, I; Tse, A
Journal:
Annals of oncology
Issue:
Volume 29:Number 11(2018)
Page Start:
2163
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 1061PMolecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial. (23rd October 2018)

Authors:
Houessinon, A; Verlingue, L; Hollebecque, A; Even, C; Lacroix, L; Postel-Vinay, S; Varga, A; El Dakdouki, Y; Balheda, R; Michot, J-M; Gazzah, A; Marabelle, A; Michiels, S; Rouleau, E; Breuskin, I; de Baere, T; Angevin, E; Scoazec, J-Y; Soria, J-C; Massard, C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 1843PMolecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial. (23rd October 2018)

Authors:
Vuagnat, P; Baldini, C; Verlingue, L; Martin Romano, P; Varga, A; Hollebecque, A; Postel-Vinay, S; Gazzah, A; Bahleda, R; Marabelle, A; Ribrag, V; Champiat, S; Michot, J-M; Soria, J-C; Massard, C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 109TiPAcSé immunotherapy trials: Anti-PD-1 therapy for adult patients with selected rare cancer types. (17th December 2018)

Authors:
Marabelle, A; Chevret, S; Janot, F; Escudier, B; Pouessel, D; Tournigand, C; Hoang-Xuan, K; Mortier, L; Rousseau, B J-C; Schlumberger, M J; Ray-Coquard, I L; Blay, J-Y; Niccoli, P; Jaccard, A; Couch, D; Hoog-Labouret, N; Pauporte, I; Massard, C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. 110TiPA phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions. (17th December 2018)

Authors:
Marabelle, A; Eberst, L; Terret, C; Pilleul, F; Mastier, C; Bouhamama, A; Gilles-Afchain, L; Laurent, S; Delzano, I; Reynaud, C; Caux, C; Caux, C; Garin, G; Bidaux, A-S; Perol, D; Stojkowitz, N; Homerin, M; Leenders, H; Cassier, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗